SCHEMBL3405237

SCHEMBL3405237

CCOC(=O)CC(=O)c1cn(C)cn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.42
MGAM O43451 1/20 0.42
SI P14410 1/20 0.42
MGAM2 Q2M2H8 1/20 0.42
ALDH1A1 P00352 3/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
MITF O75030 1/20 0.39
LMNA P02545 1/20 0.37
NOTUM Q6P988 1/20 0.36
MAPT P10636 1/20 0.36
TNF P01375 3/20 0.36
TBXAS1 P24557 2/20 0.36
GSK3A P49840 1/20 0.36
GSK3B P49841 1/20 0.36
PKM P14618 1/20 0.35
KDM5A P29375 1/20 0.35
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4930966 0.85 ALDH1A1 (0.42) GAAALDH1A1KDM4EMEN1KMT2A
SCHEMBL15340711 0.82 KDM5A (0.40) GAAMGAMSIMGAM2ALDH1A1
SCHEMBL5591480 0.80 NOTUM (0.52) GAAALDH1A1KDM4EMEN1KMT2A
SCHEMBL20438538 0.78 KDM5A (0.40) GSK3BKDM5A
SCHEMBL25062488 0.76 NOTUM (0.37) GAAALDH1A1KDM4EMITFLMNA
SCHEMBL1129548 0.76 KLKB1 (0.47) ALDH1A1MEN1KMT2ALMNAKDM5A
SCHEMBL4988751 0.75 GRM2 (0.37) LMNANOTUMGSK3BKDM5ASMN1; SMN2
SCHEMBL9789313 0.74 SIRT2 (0.42) ALDH1A1LMNASMN1; SMN2
SCHEMBL14551489 0.74 MEN1 (0.43) GAAALDH1A1KDM4EMEN1KMT2A
SCHEMBL5163521 0.73 MGAM (0.44) GAAMGAMSIMGAM2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 NISCH, PIR, QDPR GAA 494/4885MGAM 3029/4885SI 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.